Evidence map›Paper›PMID 38606960›Full record

ArticlemSystems2024

Providing insight into the mechanism of action of cationic lipidated oligomers using metabolomics.

Maytham Hussein, Muhammad Bilal Hassan Mahboob, Jessica R Tait, James L Grace, Véronique Montembault, Laurent Fontaine, John F Quinn, Tony Velkov, Michael R Whittaker, Cornelia B Landersdorfer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mSystems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Maytham Hussein *Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia.
Muhammad Bilal Hassan Mahboob *Drug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Jessica R TaitDrug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.ORCID 0009-0007-3850-1555
James L GraceDrug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Véronique MontembaultInstitut des Molécules et Matériaux du Mans, UMR 6283 CNRS-Le Mans Université, Le Mans, France.
Laurent FontaineInstitut des Molécules et Matériaux du Mans, UMR 6283 CNRS-Le Mans Université, Le Mans, France.
John F QuinnDrug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Tony VelkovDepartment of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia.
Michael R WhittakerDrug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Cornelia B LandersdorferDrug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.ORCID 0000-0003-0928-4743
Monash University · AUCentre National de la Recherche Scientifique · FRThe University of Melbourne · AU

Funding

Department of Education and Training | Australian Research Council (ARC) DP200102829Department of Education and Training | Australian Research Council (ARC) FT170100144DHAC | National Health and Medical Research Council (NHMRC) GNT1159579
6 · The paper itself

Abstract

The increasing resistance of clinically relevant microbes against current commercially available antimicrobials underpins the urgent need for alternative and novel treatment strategies. Cationic lipidated oligomers (CLOs) are innovative alternatives to antimicrobial peptides and have reported antimicrobial potential. An understanding of their antimicrobial mechanism of action is required to rationally design future treatment strategies for CLOs, either in monotherapy or synergistic combinations. In the present study, metabolomics was used to investigate the potential metabolic pathways involved in the mechanisms of antibacterial activity of one CLO, C

Indexed as

Anti-Bacterial AgentsMetabolomicsMethicillin-Resistant Staphylococcus aureusCationsMicrobial Sensitivity TestsAnti-Bacterial AgentsCationsantimicrobial peptidesantimicrobial polymerantimicrobial resistancecationic lipidated oligomersmetabolomicsmethicillin-resistant Staphylococcus aureuspeptidoglycan biosynthesis

Identifiers

PMID38606960
PMCPMC11097639
OpenAlexW4394734774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.